Dror Ortho-Design, Inc. 8-K

What Happened

• Dror Ortho-Design, Inc. filed an 8‑K disclosing that on December 30, 2025 it entered a Securities Purchase Agreement to sell $250,000 of debentures in a private placement. The debentures bear 0% interest and mature on February 28, 2026 (holder may extend maturity in 60‑day increments). The transaction closed December 30, 2025 and was conducted under Regulation D/Section 4(a)(2) with accredited investor purchasers.

Key Details

• Aggregate principal: $250,000; closing date: December 30, 2025; filing date: January 6, 2026.
• Debentures: 0% interest; maturity February 28, 2026; holders may extend maturity by 60 days; Company may prepay subject to conditions.
• Conversion: If the Company completes a public offering, outstanding debentures automatically convert into common stock at the public offering price; converted shares receive the same terms as offering shares (including any warrants and registration rights). Conversion is subject to a holder cap of 9.99% of outstanding common stock (adjustable with notice).
• Warrants: Purchasers are to receive contingent warrants tied to a future public offering (Purchase Warrants and Additional Warrants). If issued, warrants would be exercisable immediately, have a 5‑year term, exercise price equal to the public offering price, and include customary anti‑dilution adjustments. The Company does not intend to list the warrants.
• Placement terms: Private placement exempt under Reg D; purchasers represented they are accredited and purchased for investment, no general solicitation.

Why It Matters

• This is short‑term financing (matures Feb 28, 2026) that provides $250K of capital now but is structured to convert into equity if the company completes a public offering. Automatic conversion and issuance of related warrants upon a public offering would increase shares outstanding and could dilute existing shareholders.
• Investors should monitor whether Dror completes a public offering (which triggers conversion and warrant issuance), and watch related filings for the conversion price, number of shares issued, and any future dilution or registration rights.